Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses
Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections Virpax Pharmaceuticals Inc. (“Virpax”), today announced the signing of a technology license agreement with Nanomerics Ltd. (“Nanomerics”) for the exclusive North America rights to use Nanomerics’ High-Density Molecular Masking Spray (MMS019) for the prevention of seasonal influenza [...]
Vanila M. Singh, MD, MACM Elected to Virpax Pharmaceuticals’ Board of Directors
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the election of Vanila M. Singh, MD, MACM, to its Board of Directors. Dr. Singh was the immediate past Chief Medical Officer in [...]
Virpax Pharmaceuticals Announces Appointment of Christopher M. Chipman, Chief Financial Officer
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Christopher M. Chipman, CPA, Chief Financial Officer. “As Chairman of the Audit Committee, it is with great pleasure that I welcome Chris [...]
[FEATURED] Is Biopharma Still Committed To Its Role In Public Health?
This article from Life Science Leader magazine features the views of top executives, including Virpax's CEO Anthony Mack, on how the life sciences industry business model meets public health obligations. Read more on lifescienceleader.com
Virpax Pharmaceuticals Reports Pre-IND Guidance From FDA for DSF100
505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase 1 Human Study Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, received a written response from the US Food and [...]
[FEATURED] Virpax inks ‘patch-in-a-can’ deal for pain management
Virpax Pharmaceuticals has licensed MedPharm’s topical spray technology to develop a transdermal patch for non-opioid pain management products. Read more on in-pharmatechnologist.com
Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure
Virpax to Develop a Long-Acting Liposomal Gel (Lipogel) for Post-Operative Pain Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. [...]
Virpax Pharmaceuticals Licenses ‘Patch-in-a-Can’ MedSpray® Technology From MedPharm Ltd
Transdermal Delivery Technology Integrated Into DSF100 NSAID Spray Film 1.3% Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with MedPharm Ltd, a leading contract provider of topical and transdermal product design and [...]